OncoImmune pulls in $56M Series B, hoping GvHD program can prove useful for Covid-19
A little over three and a half years since coming out of stealth, OncoImmune is back with a new fundraise.
The Maryland-based biotech announced a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
